Pyxis Oncology (PYXS) Return on Capital Employed (2021 - 2026)
Pyxis Oncology (PYXS) posted quarterly Return on Capital Employed of 109.03% for Q4 2025, down 5261.0% year-over-year from 2.11% in Q4 2024, and up 2.44% quarter-over-quarter from 111.75% in Q3 2025.
Pyxis Oncology (PYXS) Return on Capital Employed (2021 - 2026) Analysis & Trends
Pyxis Oncology (PYXS) has reported Return on Capital Employed for 5 consecutive years, with 109.03% the latest figure, recorded in Q4 2025.
- In Q4 2025, Return on Capital Employed fell 5261.0% year-over-year to 109.03%; the TTM figure through Dec 2025 stood at 109.03% (down 5261.0% YoY), while the FY2025 annual figure was 81.79%, down 2125.0% from the prior year.
- Return on Capital Employed rose to 109.03% in Q4 2025 per PYXS's latest filing, from 111.75% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 26.45% in Q1 2022 and bottomed at 111.75% in Q3 2025.
- Historically, Return on Capital Employed has averaged 59.91% across 5 years, with a median of 56.42% in 2024.
- Annual changes were most pronounced in 2024 — Return on Capital Employed surged 3010 bps — and 2025, when it sank 7476 bps.
- Pyxis Oncology's Return on Capital Employed stood at 36.49% in 2021, then sank by 82 bps to 66.39% in 2022, then grew by 20 bps to 53.22% in 2023, then declined by 6 bps to 56.42% in 2024, then slumped by 93 bps to 109.03% in 2025.
- Business Quant data shows PYXS's Return on Capital Employed at 109.03% in Q4 2025, 111.75% in Q3 2025, and 95.19% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Pyxis Oncology | 198.37 Mn | 165.38 Mn | - | -191.26% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -191.26% |
| Dec 31, 2025 | -109.03% |
| Sep 30, 2025 | -111.75% |
| Jun 30, 2025 | -95.19% |
| Mar 31, 2025 | -80.83% |
| Dec 31, 2024 | -56.42% |
| Sep 30, 2024 | -37.00% |
| Jun 30, 2024 | -34.83% |
| Mar 31, 2024 | -36.56% |
| Dec 31, 2023 | -53.22% |
| Sep 30, 2023 | -67.09% |
| Jun 30, 2023 | -62.10% |
| Mar 31, 2023 | -60.94% |
| Dec 31, 2022 | -66.39% |
| Sep 30, 2022 | -47.60% |
| Jun 30, 2022 | -36.59% |
| Mar 31, 2022 | -26.45% |
| Dec 31, 2021 | -36.49% |